Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.65 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612192 | 0.90 | SCN9A (0.54) | SCN9ASCN10AGRM5MAPTTP53 | |
| SCHEMBL4492628 | 0.89 | SCN9A (0.57) | SCN9ASCN10AGRM5MAPTTP53 | |
| SCHEMBL4477859 | 0.86 | SCN9A (0.60) | SCN9ASCN10AGRM5 | |
| SCHEMBL4612818 | 0.86 | SCN9A (0.56) | SCN9ASCN10AGRM5 | |
| SCHEMBL1400101 | 0.84 | SCN9A (0.69) | SCN9ASCN10AGRM5 | |
| SCHEMBL14269692 | 0.78 | SCN9A (0.57) | SCN9ASCN10AGRM5 | |
| SCHEMBL4498041 | 0.78 | SCN9A (0.57) | SCN9ASCN10AGRM5 | |
| SCHEMBL5928783 | 0.78 | SCN9A (0.52) | SCN9ASCN10AGRM5MAPTTP53 | |
| SCHEMBL4499658 | 0.77 | SCN9A (0.56) | SCN9ASCN10AGRM5 | |
| SCHEMBL1400398 | 0.77 | SCN9A (0.57) | SCN9ASCN10AGRM5MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | MERCK SHARP & DOHME LLC | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885SCN10A 68/4885ABL1 1341/4885 |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | SCN3A, TRPV1, KCNN3 | SCN9A 67/4885SCN10A 117/4885ABL1 1816/4885 |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885SCN10A 68/4885ABL1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.